We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Investors Undervaluing Avanos Medical (AVNS) Right Now?
Read MoreHide Full Article
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.
Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.
One company value investors might notice is Avanos Medical (AVNS - Free Report) . AVNS is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. The stock holds a P/E ratio of 12.94, while its industry has an average P/E of 32.36. Over the past 52 weeks, AVNS's Forward P/E has been as high as 21.37 and as low as 11.70, with a median of 13.44.
AVNS is also sporting a PEG ratio of 0.99. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. AVNS's PEG compares to its industry's average PEG of 2.59. Over the last 12 months, AVNS's PEG has been as high as 1.72 and as low as 0.98, with a median of 1.09.
Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. AVNS has a P/S ratio of 1.25. This compares to its industry's average P/S of 2.91.
Another great Medical - Instruments stock you could consider is Elekta (EKTAY - Free Report) , which is a # 2 (Buy) stock with a Value Score of A.
Furthermore, Elekta holds a P/B ratio of 2.37 and its industry's price-to-book ratio is 4.30. EKTAY's P/B has been as high as 3.47, as low as 2.23, with a median of 2.76 over the past 12 months.
These figures are just a handful of the metrics value investors tend to look at, but they help show that Avanos Medical and Elekta are likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, AVNS and EKTAY feels like a great value stock at the moment.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Investors Undervaluing Avanos Medical (AVNS) Right Now?
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.
Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.
One company value investors might notice is Avanos Medical (AVNS - Free Report) . AVNS is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. The stock holds a P/E ratio of 12.94, while its industry has an average P/E of 32.36. Over the past 52 weeks, AVNS's Forward P/E has been as high as 21.37 and as low as 11.70, with a median of 13.44.
AVNS is also sporting a PEG ratio of 0.99. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. AVNS's PEG compares to its industry's average PEG of 2.59. Over the last 12 months, AVNS's PEG has been as high as 1.72 and as low as 0.98, with a median of 1.09.
Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. AVNS has a P/S ratio of 1.25. This compares to its industry's average P/S of 2.91.
Another great Medical - Instruments stock you could consider is Elekta (EKTAY - Free Report) , which is a # 2 (Buy) stock with a Value Score of A.
Furthermore, Elekta holds a P/B ratio of 2.37 and its industry's price-to-book ratio is 4.30. EKTAY's P/B has been as high as 3.47, as low as 2.23, with a median of 2.76 over the past 12 months.
These figures are just a handful of the metrics value investors tend to look at, but they help show that Avanos Medical and Elekta are likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, AVNS and EKTAY feels like a great value stock at the moment.